top of page
logo_edited.png
Latest News

Updates, press releases & new papers

Minister Jan Jambon visits remynd

27 May 2025

We were pleased to welcome Federal Minister Jan Jambon this week for a visit at our facilities in Leuven, where he was introduced to our ongoing work in Alzheimer research and drug development.

Remynd tests optimized septin modulator against Alzheimer’s disease in phase 1 clinical trial

7 May 2025

Our ongoing Phase I study is progressing as planned, with the first results expected in early July.

Unlearn and remynd partner to strengthen confidence in early clinical signals using digital twins

3 Apr 2025

AI-powered digital twins help interpret early signals in a small Phase 2a study of a novel therapy for Alzheimer’s disease

Remynd strenghtens drug development focus with strategic sale of CRO business to InnoSer

4 Mar 2025

Leuven biotech player remynd announces its strategic transition into an organization purely focused on drug development

remynd announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease

30 Oct 2024

Results were presented this week at the 17th annual Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid

reMYND appoints new CEO and Chairman to progress novel Alzheimer’s Disease program through clinical development

3 Sept 2024

remynd announces appointment of Floor Stam as CEO and Johan Cardoen as Chairman

Pharmacological modulation of septins is neuroprotective in models of Alzheimer’s disease

5 Aug 2024

We published a new study in Science revealing a promising strategy to combat Alzheimer’s disease.

Get in touch

Remynd is located in the Arenberg Science Park, a hub of innovation and research. Our labs and offices are situated in the Bio Incubator 3 building.

bottom of page